Modulation of redox balance leaves murine diabetogenic TH1 T cells "LAG-3-ing" behind

Diabetes

Volumn 61, Issue 7, 2012, Pages 1760-1768

  Delmastro, Meghan M ^a,b   Styche, Alexis J ^a   Trucco, Massimo M ^a,b   Workman, Creg J ^c   Vignali, Dario A A ^c   Piganelli, Jon D ^a,b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LYMPHOCYTE ACTIVATION GENE 3; LYMPHOCYTE ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETOGENESIS; DISEASE COURSE; EFFECTOR CELL; ENZYME ACTIVITY; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ADAM PROTEINS; ANIMALS; ANTIGENS, CD; BIOLOGICAL MARKERS; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; FEMALE; LYMPHOCYTE ACTIVATION; MANGANESE; METALLOPORPHYRINS; MICE; MICE, INBRED NOD; OXIDATION-REDUCTION; SUPEROXIDE DISMUTASE; TH1 CELLS;

EID: 84863188195     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1591     Document Type: Article

References (47)

1. Delmastro MM, Piganelli JD. Oxidative stress and redox modulation potential in type 1 diabetes. Clin Dev Immunol 2011;2011:593863
2. Batinić-Haberle I, Benov L, Spasojević I, Fridovich I. The ortho effect makes manganese(III) meso-tetrakis(N-methylpyridinium-2-yl) porphyrin a powerful and potentially useful superoxide dismutase mimic. J Biol Chem 1998;273:24521-24528 (Pubitemid 28454947)
3. Day BJ, Batinic-Haberle I, Crapo JD. Metalloporphyrins are potent inhibitors of lipid peroxidation. Free Radic Biol Med 1999;26:730-736 (Pubitemid 29146277)
4. Tse HM, Milton MJ, Piganelli JD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic Biol Med 2004;36:233-247 (Pubitemid 38117241)
5. Tse HM, Milton MJ, Schreiner S, Profozich JL, Trucco M, Piganelli JD. Disruption of innate-mediated proinflammatory cytokine and reactive oxygen species third signal leads to antigen-specific hyporesponsiveness. J Immunol 2007;178:908-917 (Pubitemid 46095163)
6. Sklavos MM, Tse HM, Piganelli JD. Redox modulation inhibits CD8 T cell effector function. Free Radic Biol Med 2008;45:1477-1486
7. Sklavos MM, Bertera S, Tse HM, et al. Redox modulation protects islets from transplant-related injury. Diabetes 2010;59:1731-1738
8. Piganelli JD, Flores SC, Cruz C, et al. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 2002;51:347-355 (Pubitemid 34764789)
9. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008;29:258-289
10. Nelson KK, Melendez JA. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 2004;37:768-784 (Pubitemid 39078549)
11. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990;87:5578-5582
12. Wang Y, Herrera AH, Li Y, Belani KK, Walcheck B. Regulation of mature ADAM17 by redox agents for L-selectin shedding. J Immunol 2009;182:2449-2457
13. Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol 2003;54:101-123 (Pubitemid 137639466)
14. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733 (Pubitemid 27098094)
15. Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol 1998;10:654-659 (Pubitemid 28477025)
16. Li N, Wang Y, Forbes K, et al. Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J 2007;26:494-504 (Pubitemid 46160949)
17. Moss ML, Jin SL, Becherer JD, et al. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol 1997;72:127-129 (Pubitemid 27062767)
18. Moss ML, White JM, Lambert MH, Andrews RC. TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today 2001;6:417-426 (Pubitemid 32328296)
19. Bruniquel D, Borie N, Hannier S, Triebel F. Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II. Immunogenetics 1998;48:116-124 (Pubitemid 28302314)
20. Workman CJ, Wang Y, El Kasmi KC, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 2009;182:1885-1891
21. Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 2003;33:970-979 (Pubitemid 36546685)
22. Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 1995;25:2718-2721
23. Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005;115:170-178 (Pubitemid 40733402)
24. Okazaki T, Okazaki IM, Wang J, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med 2011;208:395-407
25. Bettini M, Szymczak-Workman AL, Forbes K, et al. Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol 2011;187:3493-3498
26. Triebel F, Hacene K, Pichon MF. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett 2006;235:147-153
27. Li N, Workman CJ, Martin SM, Vignali DA. Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223). J Immunol 2004;173:6806-6812 (Pubitemid 39541066)
28. Yoshida K, Martin T, Yamamoto K, et al. Evidence for shared recognition of a peptide ligand by a diverse panel of non-obese diabetic mice-derived, islet-specific, diabetogenic T cell clones. Int Immunol 2002;14:1439-1447 (Pubitemid 36024610)
29. Coudriet GM, He J, Trucco M, Mars WM, Piganelli JD. Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. PLoS ONE 2010;5:e15384
30. Haskins K. Pathogenic T-cell clones in autoimmune diabetes: more lessons from the NOD mouse. Adv Immunol 2005;87:123-162 (Pubitemid 41133493)
31. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173 (Pubitemid 19138011)
32. Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 2004;172:5450-5455 (Pubitemid 38542045)
33. Workman CJ, Dugger KJ, Vignali DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol 2002;169:5392-5395 (Pubitemid 35291633)
34. Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007;117:3383-3392 (Pubitemid 350096994)
35. Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DA. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol 2002;32:2255-2263 (Pubitemid 34965888)
36. Scala E, Carbonari M, Del Porto P, et al. Lymphocyte activation gene-3 (LAG-3) expression and IFN-gamma production are variably coregulated in different human T lymphocyte subpopulations. J Immunol 1998;161:489-493 (Pubitemid 28285559)
37. Woo SR, Li N, Bruno TC, et al. Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol 2010;40:1768-1777
38. Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 2005;174:688-695 (Pubitemid 40094261)
39. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity 2004;21:503-513 (Pubitemid 39370506)
40. Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 2000;190:150-156 (Pubitemid 30082487)
41. Adelstein S, Pritchard-Briscoe H, Anderson TA, et al. Induction of self-tolerance in T cells but not B cells of transgenic mice expressing little self antigen. Science 1991;251:1223-1225 (Pubitemid 21926216)
42. Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010;11:21-27
43. Serreze DV, Johnson EA, Chapman HD, et al. Autoreactive diabetogenic T-cells in NOD mice can efficiently expand from a greatly reduced precursor pool. Diabetes 2001;50:1992-2000 (Pubitemid 33643665)
44. Tousseyn T, Thathiah A, Jorissen E, et al. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. J Biol Chem 2009;284:11738-11747
45. Okamura T, Fujio K, Shibuya M, et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci U S A 2009;106:13974-13979
46. Haudebourg T, Dugast AS, Coulon F, Usal C, Triebel F, Vanhove B. Depletion of LAG-3 positive cells in cardiac allograft reveals their role in rejection and tolerance. Transplantation 2007;84:1500-1506 (Pubitemid 350294726)
47. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011;91:79-118